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Available online 17 May 2017AbstractAim: The aim of the present study was to evaluate the risk of axillary non-sentinel lymph-node metastases (ALN) in breast cancer patients
presenting macrometastasis (Mac-m) in the sentinel lymph node (SN).
Materials and methods: A retrospective series of 1464 breast cancers from patients who underwent ALN dissection following the diagnosis
of Mac-m in the sentinel node (SN) was studied. In all the cases the MAC-m linear size was evaluated and correlated with presence or
absence of non-SN ALN metastases.
Results: Non-SN metastases were detected in 644y1464 cases (43.98%). The risk of further axillary metastases ranged from 20.2% (37/
183) in cases with Mac-m between 2 and 2.9 mm, to 65.3% (262/401) in cases with Mac-m measuring > 10 mm. The risk of non-SN ALN
metastases showed a 3% increase, parallel to each mm increment in SN metastasis size. The data evaluated with the receiver operating
characteristic (ROC) curve showed that the Mac-m could be subdivided according to a new cut-off of 7 mm. pT1 tumours, with Mac-m
< 7 mm had a risk of non-SN ALN metastases of <30%. Furthermore 109/127 of these (85.8%) had 3 or less non-SN ALN -metastases.
Conclusions: The present data give a detailed description on the risk of non-SN ALN involvement, that may be useful in the evaluation of
breast cancer patients. It is suggested that a Mac-m size of <7 mm is related to a low residual axillary disease burden in breast cancer
patients with small (pT1) tumours.
 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
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1422 M.P. Foschini et al. / EJSO 43 (2017) 1421e1427Introduction On the other side, the arbitrary cut-off size to separateIn patients with breast cancer, the wide application of
SN biopsy (SNB) has led to a reduction of side effects
occurring after axillary lymph node dissection (ALND).
SNs free of metastatic deposits, can reliably predict the
absence of further metastases in the axilla.6 It is similarly
clear that the presence or absence of metastatic deposits
in the SN(s) cannot be the only feature to be evaluated,
to predict further axillary node (ALN) involvement.1,2
The size of the metastatic deposits has been one of the
most important and most studied parameters in this re-
spect.5e7 It has been evident that small volumemetastatic de-
posits in the SN were related to a low risk of further axillary
metastases. Therefore, the SN metastatic deposits were arbi-
trarily classified into three size categories: isolated tumour
cells (ITC) when not greater than 0.2 mm; micrometastasis
(Mic-m) when between 0.2 and 2 mm and macrometastasis
(Mac-m) when larger than 2 mm.These definitions, with
some refinements, are currently applied in SN evaluation.8
Despite the diagnostic problems and pitfalls,9e12 it is
evident that small volume metastatic deposits correspond
to a low risk of further axillary involvement.13 Accordingly,
the presence of ITCs, even if related to a small increase in
the risk of axillary metastases14 was not considered enough
to perform ALDN, which at that time was limited to pa-
tients with Mic-m and Mac-m.
In 2011, Giuliano et al.15 demonstrated that selected pa-
tients with metastatic disease, including Mic-m and limited
Mac-m, can safely avoid ALND, when breast conserving
surgery is combined with whole breast irradiation (RT)
and patients receive adjuvant systemic treatment (mostly
chemotherapy, CHT) as well. The results of the American
College of Surgeons Oncology Group (ACOSOG) Z0011
trial published by Giuliano et al.,15 even if subject to criti-
cisms,16 have significantly changed the practice of axillary
treatment in breast cancer, and have initiated a large scale
validation study, the POSNOC (POsitive Sentinel NOde-
adjuvant therapy alone versus adjuvant therapy plus Clear-
ance or axillary radiotherapy) trial which aims to overcome
the criticized aspects of the ACOSOG Z0011 trial.17 Two
other randomized trials also support the omission of
ALND in cases of SN Mic-m.18,19 Therefore, recently pub-
lished guidelines, accept that ALND can be avoided in pa-
tients with early stage breast cancer and Mic-m, when
matching the selection criteria of the Z0011 trial.1,2
Avoiding ALND in appropriately selected patients is ex-
pected to harbour no or very limited tumour burden in the
axilla and greatly reduces the risk of local complications,
leading to a better quality of life for patients without
increasing the risk of disease recurrence.
In daily practice, it is evident that even patients with
Mac-m in the SN who undergo ALND, are frequently
free of further metastatic deposits, and in retrospect, receive
unnecessary surgery with the potential risk of local
complications.Mic-m from Mac-m, currently established at 2 mm based
on a historical work by Huvos and colleagues introducing
the term Mic-m,20 has been proposed without being vali-
dated in large series.
Recently Illyes et al.,21 proposed that the 2 mm cut-off,
could be modified to 6 mm, allowing the avoidance of
completion ALND in a larger proportion of patients.
In addition, numerous papers demonstrated that the size
of the metastatic deposit in the SN is not the only parameter
to consider the risk evaluation of further axillary involve-
ment. Indeed, size and grade of the primary tumour, multi-
focality, presence of lympho-vascular invasion (LVI), extra
capsular extension (ECE), are important parameters
predicting the risk of further axillary involvement.3,4,22e24
Therefore, the aim of the present study was to retrospec-
tively evaluate a large multi-institutional series of MAC-m
in the SN with patients who underwent ALND, and to
correlate the presence of further lymph-node metastatic
involvement with the Mac-m linear size and primary
tumour features. The final goal of the study was to provide
data useful to evaluate the real risk of further axillary
involvement in each breast cancer patient, in order to better
tailor therapeutic planning.Materials and methods
Cases were collected retrospectively from 13 European
centres, all of which are involved in the diagnosis and treat-
ment of screen detected breast cancer patients. All centres,
but one (Imola, Bologna), are associated with the European
Working Group for Breast Screening Pathology
(EWGBSP), and therefore follow similar diagnostic proto-
cols. The Imola centre, due to its geographical location very
close to Bologna, shares the same diagnostic protocols with
the Bologna Bellaria centre, and consequently the two cen-
tres were considered together.
Cases were included when they met the following
criteria: a) SNB was performed at primary surgery for stag-
ing purposes; b) at least one SN contained a Mac-m; c)
ALND with the removal of at least 10 axillary lymph nodes
was performed in addition to the SNB; d) data on the pri-
mary tumour were available; e) no neo-adjuvant chemo-
or hormonal therapy had been administered. According to
the inclusion criteria above, cases without metastatic de-
posits, or with either Mic-m or ITC in the SN, as well as
male breast cancers were excluded. The cases therefore
represent a consecutive series meeting the inclusion criteria
from each centre.
In each case, the following parameters were evaluated:
1) largest linear size of the Mac-m, in millimetres (mm);
2) the number of SN involved by MAC-m; 3) presence of
extra capsular extension (ECE). In addition, the following
parameters were evaluated in the primary tumour: histo-
type, grade, size, presence of LVI and multifocality.
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method using both a radiocolloid (99mTc labelled albumin)
and patent blue dye. Tracer administration was either intra/
peritumoral and/or periareolar. All blue and/or hot nodes
were considered SNs, palpable removed cold and non-dye
labelled LNs were considered as non-SNs removed during
SN biopsy. Intra-operative evaluation (based on frozen sec-
tion andyor imprint cytology) was performed in about half
of the cases, but intraoperative decision to perform ALND
was based on the presence of a macrometastasis larger than
2 mm. A summary of the methods applied in the different
centres is given in Table 1S (see Supplementary files). In
general, the centres did not follow the Z0011 trial based
recommendations for the omission of ALND for cases of
macrometastatic SLNs at the time of the data collection.
The diagnosis of Mac-m was performed according to the
criteria previously published by the European Working
Group on Breast Screening Pathology (EWGBSP).9,10
Histological typing, grading and staging of the primary
tumour were performed according to currently accepted
criteria.25e27Statistical analysesTable 1
Risk of Metastatic non-SN Depending on size of Mac-M in SN.
Mac-msize in mm Number of metastatic
non-SN cases/total
number of cases
Risk of metastatic
non-SN
2.1e2.9 37/183 20.2%
3e3.9 44/157 28.1%
4e4.9 50/140 35.7%
5e5.9 52/139 37.4%Univariate analysis was used to evaluate all available
variables as individual risk factors for Mac-m SN. Distribu-
tion of continuous variables was analysed with the Wil-
coxon test, and the Chi-squared test was used for
categorical variables.
For multivariate analysis, the variables were included
into a logistic regression model using a backward stepwise
selection. Variables with a p value greater than 0.05 were
excluded from the final predictive model.
The subsequent multivariate predictive model was then
validated internally on a predefined set of data and then
through an external validation. Internal validation was
based on cases from the two centres providing the highest
number of cases (centres A and B). External validation
was performed on the remaining centres.
Discrimination power of the model was evaluated by the
area under the receiver operating characteristic (ROC) curve
and the calibration of the model by the HosmereLemeshow
goodness-of-fit test. A cut-off value of less than 30% risk of
metastatic ALNs was considered as low-risk. This cut-off
was considered on the basis of the Z0011 trial15,28 where
27% of the patients in the ALND arm showed further axillary
metastatic deposits and therefore this was the anticipated
nodal positivity rate in the arm where ALND was omitted.
Sensitivity and specificity were determined for various
risk estimates. All statistical tests were two-sided. Statisti-
cal analyses were done with STATA (ver. 12.0).6e6.9 54/148 36.5%
7e7.9 46/99 46.5%Ethical considerations
8e8.9 54/106 50.9%
9e9.9 45/91 49.5%
10 262/401 65.3%The present study did not influence patient’s treatment,
as it was performed anonymously and retrospectively.The study was approved by the Ethical Committee at
AUSL of Bologna, Italy (protocol n. 15080).
Results
A total of 1464 cases met the inclusion criteria and were
collected for the present study.
All the patients were female, aged from 26 to 91 (mean:
58.5, median 58).
Tumour histotype was: ductal, no special type (NST) in
1094 cases (74.7%); lobular in 178 cases (12.2); special
types in 192 cases (13.1%). As the number of special
type carcinomas was small, they were evaluated altogether.
Tumour size ranged from 0.2 to 16 cm, approximately
half of the cases (760/1464, 51.9%) were between 1.5
and 2.5 cm (mean 2.2 cm; median 1.9 cm).
The average number of SNs examined was 2 (median 2).
The total number of non-SN, ALN examined was on
average 15.4 (median 14, range from 10 to 35).
Non-SN metastases were detected in 644 cases (44%).
The number of non-SNs with metastatic deposits ranged
between 1 and 35 (median mean: 3.8); 436 of 644 cases
(67.6%) presented  3 non-SN involved.ALN metastases in relation to the Mac-m size:
Tables 1 and 2The risk of further axillary metastases ranged from
20.2% (37/183) in cases with MAC-m between 2.1 and
2.9 mm, to 65.3% (262/401) in cases with Mac-m
measuring > 10 mm.
The risk of having metastatic non-SN ALNs was studied
using a binary logistic regression model estimated on the
internal validation series, based on cases from centres A
and B.
The logarithm of Mac-m size in each centre’s series, his-
tological tumour size, multifocality of the primary tumour,
age (in classes: 26e40, 41e50, 51e60, 61e70 and over 70
years, the last group representing the reference category),
number of SN metastasis, total number of SNs had a p
-value of less than 0.05 and were included in the multivar-
iate analysis after a backward selection procedure.
Table 2
Final predicted model using Mac-m size 7 mm.
Coef. P-value [95% Conf. Interval] Odds Ratio
Mac-m  7 0.91 <0.001 [0.62e1.21] 2.50
Tumour focality
(Yes/No)
0.25 <0.001 [0.13e0.37] 1.28
Age 26e40 0.34 0.051 [0.68e0.00] 0.71
Age 41e50 0.35 <0.001 [0.53e0.16] 0.71
Age 51e60 0.44 <0.001 [0.57e0.31] 0.65
Age 61e70 0.5 <0.001 [0.6e0.4] 0.60
Age 71 and over
[reference]
1.00
Tumour size 0.03 <0.001 [0.02e0.05] 1.03
Number of SN
metastasis
0.74 0.002 [0.27e1.21] 2.10
Number of SN
examined
0.4 <0.001 [0.55e0.25] 0.67
Constant 1.56 <0.001 [2.17e0.95]
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integer cut-off values for Mac-m size and the value of
7 mm had the best discrimination power.
The final predicted model is reported in Table 3 using
Mac-m size 7 mm or greater as explanatory variables along
with the previously reported covariates.
The HosmereLemeshow test produced a p-value of
0.538 indicating that the model fits and calibrates well for
the patient population.
The ROC for the patient population used for estimating
the model was 0.713 (95% confidence interval:
0.680e0.746) suggesting a good discrimination.
The multivariate model predicted 694 (74.30%) of the
934 patients in the original patient series to have metastatic
non-SN ALN with a sensitivity of 85.58% and specificity of
35.03% at the <30% cut-off threshold.
The predictive model was then validated by insertion of
each patient’s data from the external validation series into
the equation of the binary logistic regression model. ROC
for each internal and external validation centre are given in
Table 3.Table 3
Performance of the predictive model in internal and external validation.
N % Mac-m
size  7 mm
ROC
Internal series
Centres A þ B 934 51.39 0.713
Centre A 479 50.73 0.742
Centre B 455 52.09 0.681
External validation
C 77 25.97 0.624
D 97 37.11 0.702
E 49 85.71 0.631
F 50 42.00 0.628
F1 20 30 0.818
F2 20 45 0.467
F3 10 60 0.800
G 81 37.04 0.697
H 129 49.54 0.682An equation was deduced from the logistic regression
analysis to predict a patient specific risk of having metasta-
tic non-SNs, with p denoting the probability of this risk:
logitðpÞ ¼ 1:56þ 0:91)aþ 0:25)b 0:34)c 0:35)d
 0:44)e 0:5)f þ 0:03)gþ 0:74)h 0:4)i
The letters in the equation denote the following vari-
ables: a ¼ Mac-m  7 mm (0 if not present, 1 if present),
b ¼ tumour multifocality(0 if not present, 1 if present),
c ¼ age 26e40(0 if not present, 1 if present), d ¼ age
41e50(0 if not present, 1 if present), e ¼ age 51e60 (0
if not present, 1 if present), f ¼ age 61e70(0 if not present,
1 if present), g ¼ tumour size(mm), h ¼ number of SNs
with metastasis and i ¼ total number of SNs.
The predictive model is also provided as an excel-based
calculator in the online only version of this article and at
thewebsite of EuropeanWorkingGroup on Breast Screening
Pathology (http://www.ewgbsp.org/) (Supplementary files).ALN metastases in relation to the number of SN with
Mac-m: Table 4.The number of metastatic SNs influenced the risk of
further axillary node involvement, that ranged from
29.8% when 1 SN only presented Mac-m, to 100% in the
rare cases showing >4 metastatic SN.ALN metastases in relation with Mac-m and tumour
size: (Focus of<7 mm) (Table 5)Considering 7 mm as cut-off point and relating the pres-
ence of further axillary node metastases with the tumour
size, it is evident that pT1 cases present a risk of further
axillary metastatic involvement below 30%. The risk in-
creases to 38% in pT2 cases. On the contrary, when the
SN Mac-m is larger than 7 mm, the risk is higher than
50% in pT1c cases, reaching 84.6% in pT3y pT4 cases.
In addition, the number of non-SN ALN greatly increased
using 7 mm as cut off. Cases presenting as pT1a and
pT1b had on average 1.59 metastatic non-SNs when the
Mac-m was <7 mm, while the number of metastaticTable 4
Non-sentinel node metastases in relation to the number of SN with Mac-m.
Number of Mac-M SN Number of metastatic non-SN
cases/total number of cases
1 186/624
29.8%
2 39/116
33.6%
3 9/24
37.5%
4 or more 3/3
100%
ALN: axillary lymph-node.
Table 5
Relation between pT and further axillary metastatic involvement.
SN Mac-m pT1a þ pT1b pT1c pT2 pT3/pT4
<7 mm 19/88
21.6%
108/400
27%
99/258
38.4%
11/21
52.4%
Non-SN ALN
with MTS:
Range 1e3
Average 1.59
Range 1e12
Average 2.3
Range 1e13
Average 2.48
Range 1e13
Average 4.18
7 mm 26/45
57%
139/277
50.2%
220/349
63.0%
22/26
84.6%
Non-SN ALN
with MTS:
Range 1e21
Average 5
Range 1e28
Average 3.84
Range 1e35
Average 4.70
Range 1e22
Average 8.68
MTS: metastasis.
Table 7
ALN metastases in relation with age of the patient.
Age years Further ALN metastases
40 47/92
51.1%
41e50 125/303
41.3%
51e60 159/386
41.2%
61e70 149/375
39.7%
>71 131/261
50.2%
ALN ¼ axillary lymph-nodes.
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more.ALN metastases in relation with Mac-m and tumour
grade: (Focus of<7 mm)Tumour grade alone seemed to be unrelated to the presence
of further ALN metastases, as it ranged from 34.1% in G1 to
35.3% inG3. The mean numbers of ALNs involved bymetas-
tases were similar in G1 (2), G2 (2.2) and in G3 (2.5).ALN metastases in relation with Mac-m (Focus of
<7), grade and tumour sizeThe importance of tumour grade emerged when associ-
ated with tumour size. Specifically, among G1 cases diag-
nosed at pT1a-pT1b, 15.8% only (3/19) presented further
ALN metastases. On the contrary, the risk of further ALN
metastases increased to 21.2% (11/52) in G2 and 29.4%
(5/17) in G3 cases.
In pT1c and pT2 cases, the risk of further ALN metasta-
ses is 37.8% (37/98) for G1 cases, 26.7% (87/326) for G2
and 35.5% (83/234).ALN metastases in relation with Mac-m, ECE,
tumour multifocality and lymph-vascular invasion
(pT3 and pT4 excluded) (Table 6, Supplementary
files).Table 8
Relevant data for predicting non-sentinel node involvements for the whole
groupTumour multifocality, diagnosed when more than one
invasive carcinoma was detected, and LVI were confirmed
to be important risk factors of further ALN metastaticTable 6
Risk of further ALN metastases according to the presence of tumour multi-
focality, LVI and ECE.
Mac-m <7 mm All
Absent Present Absent Present
Multifocality 170/577
29.5%
56/169
33.1%
435/1062
41.0%
176/355
49.6%
LVI 125/434
28.8%
101/312
32.4%
281/748
37.6%
330/669
49.3%
ECE 124/479
25.9%
102/267
38.2%
243/727
33.4%
368/690
53.3%*
*P-value: <0.0001.involvement considering the cases altogether. On the con-
trary, tumour multifocality and LVI seemed to have a
limited influence on the presence of non-SN ALN metasta-
ses in the Mac-m <7 mm group.
The same phenomenon was observed considering ECE.
This parameter had impact on further ALN metastases
when the whole series was considered, while the impact
was less evident when the group of SN Mac-m <7 mm
was considered.ALN metastases in relation with Mac-m and age of
the patient (pT3 and pT4 excluded) (Table 7,
Supplementary files):Age influenced the presence or absence of further ALN
metastases in the group of Mac-m <7 mm. Patients older
than 70 or younger than 40, had a higher risk of further
ALN involvement.
A logistic regression model was estimated in the sub-
groups of patients with Mac-m <7 mm and after a back-
ward selection procedure the same variables were
selected as relevant for predicting ALN involvements for
the whole group (Table 8, supplementary files).
The ROC for the patient population, used for estimating
the model (n ¼ 454) was 0.642 (95% confidence interval:
0.586e0.698), suggested a discrete discrimination.Coef. P-value [95% Conf. Interval] Odds
Ratio
Tumour multifocality
(Yes/No)
0.11 0.05 [0.00e0.22] 1.11
Age 26e40 0.18 0.16 [0.50e0.14] 0.84
Age 41e50 0.3 0.5 [1.28e0.68] 0.74
Age 51e60 0.72 0.13 [0.97e0.47] 0.49
Age 61e70 0.88 0.14 [1.16e0.6] 0.41
Age 71 and over
[reference]
Tumour size 0.03 <0.01 [0.02e0.03] 1.03
Number of SN metastasis 0.51 0.22 [0.07e0.95] 1.66
Number of SN examined 0.32 0.17 [0.65 0.01] 0.73
Constant 0.97 0.13 [1.23e0.71]
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The exact evaluation of the axillary metastatic burden is
important as it may help to tailor therapy and avoid both
over-and under-treatment in breast cancer patients. Several
papers report on nomograms useful in the risk evaluation of
further axillary metastatic involvement in the case of SN
metastasis,7,8 but most of them are based on the well-
known classification into ITC, Mic-m and Mac-m.
It is now accepted that patients with ITC or Mic-m in the
SN should not undergo ALND,1,2 especially when further
radio and chemotherapy is planned.
Nevertheless, in daily practice, especially in centres
working mainly with screen detected breast cancers, it is
not unusual to detect cases with small Mac-m or encounter
patients who receive mastectomy and do not need any
further radiotherapy.
The presented data aim to improve correct therapeutic
planning of these latter patient groups.
The data presented demonstrate that the presence of
further axillary metastatic lymph-nodes is closely related
to the SN Mac-m linear size and the characteristics of the
primary breast tumour.
The data evaluated with the ROC curve showed that the
Mac-m could be subdivided according at a cut-off of 7 mm.
The linear size of 7 mm, proposed here, is similar to that
of 6 mm suggested in a previous study. Illyes et al. (21)
measured the size of the SN metastasis in 75 SNs contain-
ing Mac-m. According to their results, the rate of axillary
non-SN involvement was significantly higher in cases
with Mac-m measuring 6,7 and 8 mm. Therefore they sug-
gested using Mac-m size of 6 mm as the cut-off value to
mandate recommendation of ALND.
According to the results obtained here, three scenarios
appeared.
The first and more favourable was that of pT1 tumours
with Mac-m measuring less than 7 mm. The second was
that of pT3yT4 tumours with Mac-m larger than 7 mm re-
flecting a higher rate of non-SN involvement. As often hap-
pens in medicine, an intermediate group also appears,
constituted by pT2 cases or by smaller tumours with
Mac-m larger than 7 mm.
Early stage breast cancer, especially the pT1 cases, with
Mac-m smaller than 7 mm had a risk of further axillary
metastatic involvement of <30%. In addition, the large ma-
jority of the cases (109/127, 85.8%) had 3 or less non-SN
axillary metastatic lymph nodes.
Further features, as grade, multifocality, LVI and ECE
had an impact on the risk evaluation, but were less relevant
than Mac-m and tumour size.
These data are consistent with those presented in a pre-
vious study by the EWGBSP, based on small breast can-
cers, being less than 15 mm. Cserni et al.29 studied 2929
breast tumours and related the type of SN metastatic depo-
sit with further axillary involvement. According to their re-
sults, tumour and SN metastatic size were stronglycorrelated with non-SN involvement. Their rate of 38%
of Mac-m showing further axillary involvement is consis-
tent with the present 36% (292/810) of pT1 cases showing
further axillary metastases.
Subdividing Mac-m according to the herein proposed
cut-off of 7 mm, the risk of further axillary involvement
dropped to 21.6% in pT1ayT1b tumours and to 27% in
pT1c tumours.
The rates of non-SN involvement reported in this series
in pT1ayT1b tumours are not so different from the risk
observed in Mic-m, that ranges from 10 to 15% of the
cases.13,28
Cases presenting with pT2 tumours with Mac-m
<7 mm, showed a 38% risk of further axillary lymph
node involvement. However, the TNM definition of pT2 in-
cludes a wide size range from 20.1e50 mm. As the linear
regression data showed, tumour size had a significant
impact on the risk of further axillary involvement, the
nomogram considered tumour size as a continuous variable
in mm, rather than the pT categories in order to more accu-
rately classify the pT2 cases.
Cases presenting with a Mac-m >7 mm and pT3-4 tu-
mours were located at the opposite end of the spectrum,
with a risk of further axillary involvement approaching
90%. In addition, the number of metastatic non-SNs was
higher (mean 8.68, range 1e22) in this subset.
Recently published guidelines1,2 recommend the avoid-
ance of ALND in patients with 1 or 2 metastatic SNs. These
guidelines also recommend caution in patients with “large
or bulky metastatic axillary SN andyor those with gross
extranodal extension of the tumour”. In addition these rec-
ommendations state that patients with large tumours (as
T3yT4) should not undergo SNB.
The present series included only a few pT3-T4 tumours,
as cases were mainly obtained from institutions working
with screen detected breast cancers. However, the data
collected on locally advanced breast cancers further
confirm the high burden of axillary metastatic involvement
in these cancers. This is also reflected by the application of
the newly proposed 7 mm cut-off in locally advanced cases
where the risk of further axillary involvement remains high,
ranging from 61.1% when the Mac-m is < 7 mm to 84.6%
when the Mac-m is 7 mm.
Measurements of Mac-m size were derived from
formalin-fixed and paraffin-embedded sections, but it is
likely that the limit of 7 mm can also be applied to frozen
sections.
In conclusion, the present data indicate that a SN Mac-m
size of <7 mm is related to a low residual axillary disease
burden in breast cancer patients with small (pT1) tumours
and suggest that completion ALND may be avoided in
this group.
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